What is Tosk?
Tosk Inc. operates at the intersection of drug discovery and patient-centric oncology care. The company specializes in the development of small-molecule therapeutics designed to augment the safety and efficacy of current cancer treatments. By mitigating the adverse side effects associated with traditional chemotherapy and radiation, Tosk aims to improve patient outcomes significantly. Furthermore, the firm has established a robust research pipeline targeting the mutant KRAS gene, a notoriously difficult therapeutic target. Through its proprietary technology, Tosk is effectively expanding the boundaries of druggable indications, providing a scalable solution for complex oncological challenges in a global market.
How much funding has Tosk raised?
Tosk has raised a total of $6.2M across 2 funding rounds:
Private Equity
$5.4M
Private Equity
$766K
Private Equity (2011): $5.4M, investors not publicly disclosed
Private Equity (2016): $766K, investors not publicly disclosed
Key Investors in Tosk
Undisclosed Investor
An institutional investment firm specializing in late-stage biopharmaceutical growth and long-term capital appreciation.
Undisclosed Investor
A strategic capital partner focused on high-impact medical research and the commercialization of innovative oncology therapies.
Undisclosed Investor
A venture-focused entity providing essential liquidity to support the development of proprietary drug discovery platforms.
What's next for Tosk?
With the infusion of $766K, Tosk is poised to accelerate its clinical development programs and expand its research into previously undruggable genetic markers. The company's strategic roadmap involves scaling its small-molecule discovery platform to address a broader spectrum of cancer-related gene activity. As the firm transitions into more advanced stages of drug validation, the focus will likely shift toward regulatory milestones and potential commercial partnerships. By maintaining its commitment to cost-effective, high-impact therapeutic solutions, Tosk is well-positioned to disrupt the standard of care in oncology, ultimately enhancing the quality of life for patients while delivering value to its investors through sustained scientific advancement.
See full Tosk company page
